Literature DB >> 9130047

The human cytomegalovirus genes and proteins required for DNA synthesis.

D G Anders1, L A McCue.   

Abstract

Although the overall picture of HCMV DNA synthesis appears typical of the herpesviruses, some novel features are emerging. Six herpesvirus-group-common genes encode proteins that likely constitute the replication fork machinery, including a two-subunit DNA polymerase, a helicas-primase complex and a single-stranded DNA-binding protein. No homolog of the herpes simplex virus origin-binding helicase is evident, but at least one additional HCMV protein of unknown function, pUL84, appears to be required for initiation. Replication initiates within or near the large and structurally complex lytic-phase replicator, ori-Lyt, near the center of UL. Recent findings suggest that ori-Lyt-mediated initiation of DNA synthesis occurs through a mechanism distinct from that employed by herpes simplex virus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9130047     DOI: 10.1159/000150508

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  15 in total

1.  A strong negative transcriptional regulatory region between the human cytomegalovirus UL127 gene and the major immediate-early enhancer.

Authors:  C A Lundquist; J L Meier; M F Stinski
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories.

Authors:  S Chou; N S Lurain; A Weinberg; G Y Cai; P L Sharma; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  The human cytomegalovirus major immediate-early enhancer determines the efficiency of immediate-early gene transcription and viral replication in permissive cells at low multiplicity of infection.

Authors:  Hiroki Isomura; Mark F Stinski
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase.

Authors:  H S Hiemstra; N C Schloot; P A van Veelen; S J Willemen; K L Franken; J J van Rood; R R de Vries; A Chaudhuri; P O Behan; J W Drijfhout; B O Roep
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

5.  The human cytomegalovirus immediate early 2 protein dissociates cellular DNA synthesis from cyclin-dependent kinase activation.

Authors:  L Wiebusch; C Hagemeier
Journal:  EMBO J       Date:  2001-03-01       Impact factor: 11.598

6.  Human cytomegalovirus oriLyt sequence requirements.

Authors:  Y Zhu; L Huang; D G Anders
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

7.  Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides.

Authors:  Alexandra Dittmer; John C Drach; Leroy B Townsend; Anke Fischer; Elke Bogner
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Rapid genetic engineering of human cytomegalovirus by using a lambda phage linear recombination system: demonstration that pp28 (UL99) is essential for production of infectious virus.

Authors:  William J Britt; Michael Jarvis; Jun-Young Seo; Derek Drummond; Jay Nelson
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Identification of putative functional motifs in viral proteins essential for human cytomegalovirus DNA replication.

Authors:  Heng-Giap Woon; Gillian M Scott; King Lun Yiu; David H Miles; William D Rawlinson
Journal:  Virus Genes       Date:  2008-07-10       Impact factor: 2.332

10.  A cis repression sequence adjacent to the transcription start site of the human cytomegalovirus US3 gene is required to down regulate gene expression at early and late times after infection.

Authors:  P E Lashmit; M F Stinski; E A Murphy; G C Bullock
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.